Mortimer Poncz

This study identifies PF4 as a central factor in APS by showing it bridges {beta}2GPI to NETs, forming prothrombotic complexes that are targeted by APS antibodies.

This study identifies PF4 as a key regulator of HSC aging, showing that PF4 deficiency accelerates aging and that PF4 supplementation can rejuvenate aged HSCs.

This study identifies platelet factor 4 (PF4) as a mediator of endothelial antimicrobial activity, enhancing bacterial clearance and improving sepsis outcomes through clathrin-mediated endocytosis and reduced immunothrombosis.

This paper shows that m-tirofiban, a non-partial agonist of IIbβ3, effectively inhibits venous thrombosis without increasing bleeding in a mouse model.

The paper shows that lung marginated neutrophils effectively uptake endothelial-targeted nanoparticles, suggesting they are part of the reticuloendothelial system.

The paper shows that megakaryocytes are entrapped in the lungs, release cytoplasmic fragments, and undergo platelet formation, supporting a pulmonary-centric 'catch-and-release' model of thrombopoiesis.

This study introduces CAPRIs, bispecific antibodies that inhibit platelet activation by clustering G6B with ITAM receptors, showing effectiveness in preventing thrombus formation without causing bleeding.

This study shows that RUNX1 haploinsufficiency reduces megakaryocyte-biased hematopoietic progenitor cells and identifies drug targets to correct this defect.